A large molecular model (LMM)-based predictor of clinical response to the WEE1 inhibitor Debio 0123 + carboplatin therapy
DNA Damage Response (DDR) dysregulation is a major factor [...]
Real world data and artificial intelligence turn anecdote to evidence | TPM podcast #50
TPM podcast archive Genialis on LinkedIn [...]
The frequency of driver alterations in non-small cell lung cancer patients: Slovenian nationwide observational cohort trial
Next-generation sequencing (NGS) biomarker testing for all newly diagnosed [...]
Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care
The program aims to deliver better guidance for physicians [...]
Genialis™ krasID White Paper
Explore the full story behind the science and innovation [...]
Launching products in healthcare: The most important framework is flexibility | TPM podcast #49
Upcoming events Genialis on LinkedIn [...]
How to have the biggest impact on patients: a career of invention, innovation, and implementation | TPM podcast #48
Genialis presents a poster at ISMB/ECCB 2025 [...]
Assessing confidence in genetic variants identified in RNA-seq data
RNA-seq data hold significant potential for identifying genetic variants. [...]
Genialis CTO Dr. Miha Štajdohar joins EU AI action plan roundtable
Dr. Miha Štajdohar, CTO and co-founder of Genialis, was [...]
A new paradigm for generative AI drug discovery: more accurate shots on a much wider goal | TPM podcast #47
Move Fast and Try Not to Break Things: AI [...]
